

ADS/BSE/2024-25/08/05
13th August, 2024

To,
The General Manager
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street Mumbai, Maharashtra – 400 001

Sub- Outcome of the Board Meeting for the quarter ended June 30, 2024 - SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Company Code – 523031

Dear Sir,

Pursuant to the provisions of Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), we wish to inform you that the Board of Directors (the 'Board') of ADS Diagnostic Limited ('the Company') at its meeting held today i.e. Tuesday, August 13th, 2024 considered and approved the Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2024 and Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2024.

The Board Meeting commenced at 13:10 P.m. and concluded at 14:19 p.m

Thanking You
Yours Faithfully

NARAYA Digitally signed
by NARAYAN
N LAL LAL GAYARI
GAYARI Date: 2024.08.13
14:20:43 +05'30'

N.L. Gayari
CFO & Company Secretary



ADS DIAGNOSTIC LIMITED

114, SANT NAGAR, EAST OF KAILASH, NEW DELHI -110065

TEL. : 011-41622193, 41620434, FAX.: 011-41665880, ☎ : 07290037529, E-mail : adsmmedical@rediffmail.com

CIN:- L85110DL1984PLC018486, Udyam Registration Number (MSME) - UDYAM-DL-08-0007361

ADS DIAGNOSTIC LIMITED
Regd. Office: 114 Sant Nagar, East of Kailash, New Delhi 110065
www.adsdiagnosticltd.com, E-mail: -adsmedical@rediffmail.com
CIN NO. L85110DL1984PLC018486


STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30.06.2024

Particulars	Quarter Ended			Year Ended
	30.06.2024	30.06.2023	31.03.2024	31.03.2024
	Unaudited	Unaudited	Audited	Audited
1 Income from Operations				
a) Revenue from Operations (Net)	414.64	322.45	590.98	2396.20
b) Other Operating Income	5.37	3.40	3.69	9.71
Total Income (a+b)	420.01	325.84	594.67	2,405.91
2 Expenses				
a) Cost of materials Consumed	217.07	126.28	222.55	1207.00
b) Employee benefits expense	59.76	58.09	68.50	253.67
c) Depreciation and amortisation expense	3.94	4.18	3.87	16.27
d) Finance costs	3.68	7.04	15.55	57.06
e) Other expenses	126.15	125.63	234.65	621.94
Total expenses (a+b+c+d+e)	410.60	321.22	545.13	2155.96
3 Profit / (loss) before Tax and Exceptional Items (1-2)	9.40	4.62	49.54	249.95
a) Exceptional item	-	-	-	-
4 Profit / (loss) before Tax	9.40	4.62	49.54	249.95
5 Tax expenses				
a) Current Income Tax	2.89	1.16	15.28	65.72
b) Income Tax - Earlier Years	-	-	0.55	0.55
c) Deferred tax charge	(0.52)	(0.63)	0.53	(1.32)
Total Tax Expenses (a+b+c)	2.37	0.53	16.36	64.95
6 Net Profit & Loss after Tax for the period (4-5)	7.04	4.09	33.19	185.00
7 Other Comprehensive Income, Net on Income Tax				
a) i) Items that will not be reclassified to profit or loss	-	-	(1.21)	(1.21)
ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	0.31	0.31
b) i) Items that will be reclassified to profit or loss	-	-	-	-
ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Total other comprehensive income, net of income tax	-	-	(0.91)	(0.91)
8 Total comprehensive income after tax (6+7)	7.04	4.09	32.28	184.09
9 Paid-up Equity Share Capital (Face Value of Rs 10/- each)	219.28	219.28	219.28	219.28
10 Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	376.92	212.55	212.55	212.55
11 Earnings Per Share (EPS) (Rs.) (not annualised)				
a) Basic EPS	0.32	0.19	1.51	8.44
b) Diluted EPS	0.32	0.19	1.51	8.44

Notes

- The above Unaudited Financial Results were reviewed by the Audit Committee and approved by Board of Directors at their respective meetings held on 13th August, 2024.
- The Company is engaged in the business of "Trading of diagnostic medical consumables & electronic consumables, servicing of medical equipments & machines" and, therefore, has only one reportable segment in accordance with Ind AS 108 "Operating Segments".
- Figures for the previous period have been recast / regrouped / rearranged, wherever necessary, to conform to the current period's classification.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) Amendment Rules, 2016 prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and relevant amendment rules thereafter.
- These Results are also updated on the company's website URL: <http://www.adsdiagnosticltd.com>

Place : New Delhi
Date: 13th August 2024



For A D S DIAGNOSTIC LIMITED

(Signature)
Dr. Gautam Sehgal
Managing Director
DIN 00034243

ADS DIAGNOSTIC LIMITED

114, SANT NAGAR, EAST OF KAILASH, NEW DELHI -110065

TEL. : 011-41622193, 41620434, FAX.: 011-41665880, ☎ : 07290037529, E-mail : adsmedical@redi-mail.com

CIN:- L85110DL1984PLC018486, Udyam Registration Number (MSME) - UDYAM-DL-08-0007361

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY UNAUDITED FINANCIAL RESULTS

To
The Board of Directors,
A D S Diagnostic Limited
(CIN: L85110DL1984PLC018486)
114, Sant Nagar, East of Kailash,
New Delhi - 110065

We have reviewed the accompanying statement of unaudited Financial Results ('the statement') of M/s. A D S Diagnostic Limited (the "Company") for the quarter ended 30th June 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the 'Listing Regulations'), read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 (the 'Circular').

This statement, which is the responsibility of the Company's Management, has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review of the statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 'Interim Financial Reporting' (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information" performed by the Independent Auditor of the entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, specified under Section 133 of the Companies Act, 2013, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For V.N. PUROHIT & CO.
Chartered Accountants
Firm Regn. 304040E

Om Prakash Pareek
Digitally signed by
Om Prakash Pareek
Date: 2024.08.13
13:23:57 +05'30'

O.P. Pareek
Partner
Membership No. 014238
UDIN: 24014238BKAUEG7805

Place: New Delhi
Date: 13th day of August, 2024